Efficacy of N-acetylcysteine vs dexamethasone in preventing postembolization syndrome post-transarterial chemoembolization in hepatocellular carcinoma: A randomized controlled trial

Figure 1 Participant flow diagram. TACE: Transarterial chemoembolization; NAC: N-acetylcysteine; DEXA: Dexamethasone; HCC: Hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer.

Figure 2 Incidence of postembolization syndrome in the N-acetylcysteine and dexamethasone group. The χ² test was used to compare the incidence of post-embolization syndrome between the two groups. DEXA: Dexamethasone; NAC: N-acetylcysteine.

Figure 3 Dynamic albumin-bilirubin change post-conventional transarterial chemoembolization between the N-acetylcysteine and dexamethasone group. Multilevel linear regression was used to calculate the mean with 95% confidence interval of albumin-bilirubin at time-points and compare the change of albumin-bilirubin overtime between the two groups. Albumin-bilirubin changes between the groups at day 28 were not significantly different (P = 0.167). DEXA: Dexamethasone; NAC: N-acetylcysteine.